Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6017 mRNA vaccine for herpes zoster in adults 40+
NCT07354659Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of SYS6017 in herpes zoster (HZ) (7 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Solicited Adverse Events at 14 days, Unsolicited Adverse Events at 30 days and 3 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
SYS6017
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07354659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354659.